Authors' response: Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: More data on asymptomatic SARS-CoV-2 infection.

Abstract

In the post-hoc analysis of the Vaxzevria (ChAdOx1-S, AstraZeneca, Cambridge, United Kingdom) licensure trial by Emary et al. [2], the secondary outcome was named ‘asymptomatic infections and infection with unknown symptoms’. Since the outcome description was imprecise, we decided to exclude these data from our report. We agree with the authors of the letter that because of wide and overlapping confidence intervals, the relevance of Emary et al.’s findings is unclear.